Home / Business and Economy / Celon Pharma's Generic Wegovy Matches Blockbuster
Celon Pharma's Generic Wegovy Matches Blockbuster
20 Aug
Summary
- Experimental semaglutide product Reduzek showed bioequivalence.
- The generic alternative matched Novo Nordisk's drugs in study.
- Celon Pharma's shares surged over 14% on study data release.
An experimental semaglutide product named Reduzek has shown promising results in an early-stage bioequivalence study. Developed by Polish drugmaker Celon Pharma, Reduzek matched the efficacy of established blockbuster weight-loss drugs, Novo Nordisk's Wegovy and Ozempic.
These findings were released on Thursday, August 20, 2026. Following the publication of selected data from the study, Celon Pharma's stock experienced a significant surge.
The company's shares climbed 14.7%, marking their best trading day since July 2024 if the gains are sustained. This development highlights a potential new generic competitor in the lucrative weight-loss drug market.
